Assessing patient readiness for the clinical adoption of personalized medicine

Public Health Genomics

Volumn 12, Issue 3, 2009, Pages 163-169

  Issa, A M ^a   Tufail, W ^a   Hutchinson, J ^a   Tenorio, J ^a   Baliga, M Poonam ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Clinical adoption; Focus groups; Patient acceptance; Personalized medicine; Pharmacogenomics

Indexed keywords

ADOPTION; ADULT; ARTICLE; CLINICAL MEDICINE; COMPREHENSION; CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PHARMACOGENOMICS; PRIORITY JOURNAL; AGED; DIAGNOSTIC PROCEDURE; DRUG THERAPY; HEALTH SERVICE; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACOGENETICS;

ADULT; AGED; DECISION MAKING; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PATIENT COMPLIANCE; PERSONAL HEALTH SERVICES; PHARMACOGENETICS;

EID: 64549162926     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189629     Document Type: Article

References (22)

1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Steart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
2. Cohen MH, Moses ML, Pazdur R: Gleevec for the treatment of chronic myelogenous leukemia: US Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist 2002;7:390-392.
3. Evans WE, Relling MK: Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464-468.
4. Lindpaintner K: Pharmacogenetics and the future of medical practice. J Mol Med 2003;81:141-153.
5. Tsai YJ, Hoyme HE: Pharmacogenomics: the future of drug therapy. Clin Genet 2002;62:257-264.
6. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG: Availability of pharmacogenomics-based prescribing information in currently approved drugs. Pharmacogenomics J 2004;4:354-358.
7. Freudenberg-Hua Y, Freudenberg J, Winantea J, Kluck N, Cichon S, Bruss M, Propping P, Nothen MM: Systematic investigation of genetic variability in 111 human genes - implications for studying variable drug response. Pharmacogenomics J 2005;5:183-192.
8. Issa AM: Clinical applications of pharmacogenomics to adverse drug reactions. Exp Rev Clin Pharmacology 2008;1:251-260.
9. Schrag D: The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-319.
10. Quinn Patton M: Qualitative Research and Evaluation Methods, ed 3. Thousand Oaks, Sage Publications, 2002.
11. Neuman WL: Basics of Social Research: Qualitative and Quantitative Approaches. Boston, Pearson, 2007.
12. Strauss A, Corbin J: Grounded theory in practice. London, Sage Publications, 1997.
13. Berth H, Balck F, Dinkel A: Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population. Genet Test 2002;6:273-280.
14. Sorenson JR, Cheuvront B, DeVellis B, Callanan N, Silverman L, Koch G, Sharp T, Fernald G: Acceptance of home and clinic-based cystic fibrosis carrier education and testing by first, second, and third degree relatives of cystic fibrosis patients. Am J Med Gen 1997;70:121-129.
15. Cappelli M, Surh L, Humphreys L, Verma S, Logan D, Hunter A, Allanson J: Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. Qual Life Res 2001;10:595-607.
16. Issa AM: Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol Sci 2000;21:247-249.
17. Issa AM: Perspectives in pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002;1:300-308.
18. Nebert DW, Bingham E: Pharmacogenomics: out of the lab and into the community. Trends Biotechnol 2001;19:519-523.
19. Thomas SM: Pharmacogenetics: the ethical context. Pharmacogenomics J 2001;1:239-242.
20. Almarsdottir AB, Bjornsdottir I, Traulsen JM: A lay prescription for tailor-made drugs - focus group reflections on pharmacogenomics. Health Policy 2005;71:233-241.
21. Gafni A: Willingness-to-pay as a measure of benefits: relevant questions in the context of public decision making about health care programs. Med Care 1991;29:1246-1252.
22. Dranitsaris G: A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Care Cancer 1997;5:489-499.